EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> ASIT Biotech added to its financing round. The biotech will use the money to move its grass pollen rhinitis treatment into a second phase 3 trial later this year. Release

> Prokarium raised $10 million (€8 million) to support clinical development of vaccines against chlamydia, Clostridium difficile and enteric fever. The British biotech is also expanding its R&D team ahead of a push into immuno-oncology. Statement 

> Bavarian Nordic and AstraZeneca agreed to trial CV301 with Imfinzi. The phase 1/2 trial will assess Bavarian’s cancer vaccine and AstraZeneca’s PD-L1 inhibitor in patients with metastatic colorectal or pancreatic cancers. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Valneva and Emergent Biosolutions moved their Zika virus vaccine into phase 1. Data from the trial will dictate whether Emergent exercises its option on the vaccine. Statement

> OSE Immunotherapeutics got the green light to resume enrollment in its Tedopi phase 3. The biotech halted enrollment in the trial last year “due to an emerging benefit/risk balance of the experimental treatment.” Release

> The Brexit Health Alliance set out how negotiators can mitigate the effect of the U.K.’s departure from the European Union on medical research. Report (PDF)

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.